Charles & Colvard Addresses Proxy Costs, Governance and Liquidity

An announcement from Charles & Colvard ( (CTHR) ) is now available.

On February 19, 2026, the disinterested members of Charles & Colvard’s Board of Directors approved reimbursing $406,188.72 in reasonable and necessary expenses to shareholder Riverstyx Fund, LP and director Duc Pham for costs incurred in a previously disclosed proxy solicitation for the company’s 2025 Annual Meeting of Shareholders. The interested directors recused themselves, and the Board cited shared governance benefits, majority shareholder support for the dissident nominees, customary practice in proxy contest settlements, and the need to defer payment until the company’s financial position improves, underscoring both governance changes and liquidity considerations for stakeholders.

The most recent analyst rating on (CTHR) stock is a Hold with a $0.50 price target. To see the full list of analyst forecasts on Charles & Colvard stock, see the CTHR Stock Forecast page.

Spark’s Take on CTHR Stock

According to Spark, TipRanks’ AI Analyst, CTHR is a Neutral.

Charles & Colvard’s stock score is significantly impacted by its poor financial performance and valuation. The company’s strategic move to secure a convertible note agreement provides some positive outlook. However, technical indicators suggest a bearish trend, and the lack of earnings call data prevents a more comprehensive analysis.

To see Spark’s full report on CTHR stock, click here.

More about Charles & Colvard

Charles & Colvard, Ltd. operates in the jewelry industry, best known for its lab-created gemstones and moissanite jewelry products. The company focuses on ethically sourced, affordable alternatives to traditional mined gemstones, targeting value-conscious and sustainability-minded consumers in the fine jewelry market.

Average Trading Volume: 5,235

Technical Sentiment Signal: Sell

Current Market Cap: $228K

For a thorough assessment of CTHR stock, go to TipRanks’ Stock Analysis page.